Αρχειοθήκη ιστολογίου

Πέμπτη 12 Οκτωβρίου 2017

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

NEJM_PC_global_header.gif

Disease indications for drugs have conventionally been defined by pathologic processes, signs or symptoms, or histologic findings in affected organs. Oncology has defined subtypes of organ-specific cancers on the basis of tumor markers; in many instances, markers are used to select patients who may…

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2wQPuQS
στις

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Εγγραφή σε: Σχόλια ανάρτησης (Atom)